STOCK TITAN

Castle Biosciences, Inc. - CSTL STOCK NEWS

Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.

Castle Biosciences, Inc. (symbol: CSTL) is a pioneering company specializing in diagnostic tests for a variety of cancers. Founded in 2008, Castle Biosciences has dedicated itself to advancing cancer care through objective and accurate testing. The company's primary mission is to provide physicians and patients with personalized, clinically actionable genomic information to facilitate more precise treatment decisions.

Castle Biosciences offers a range of diagnostic tests that assist doctors in the treatment of various cancers. Their current product portfolio includes tests for cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma, and glioma. Notably, their products include DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME, all designed to provide vital information that can influence the course of cancer treatment.

The company is not just limited to its existing portfolio; it actively engages in research programs aimed at developing diagnostic tests for other under-served cancers, such as rectal cancer and soft tissue sarcoma. These initiatives underscore Castle Biosciences' commitment to addressing gaps in cancer diagnostics and improving patient outcomes.

Castle Biosciences collaborates closely with leading members of the oncology community to ensure that their tests are both innovative and clinically relevant. This collaboration spans the discovery, development, and practical utilization of their diagnostic tests, reinforcing their standing as a crucial player in the field of cancer diagnostics.

The company is currently in a robust financial condition, reflecting its successful commercialization efforts and consistent revenue growth. Recent achievements include expanding their test portfolio and forging strategic partnerships aimed at broadening their market reach and enhancing their technological capabilities.

For the latest updates and detailed information on Castle Biosciences, Inc. and its products, please visit their official website at www.castlebiosciences.com.

Rhea-AI Summary
Castle Biosciences reports Q2 2023 revenue of $50.1 million, a 44% increase YoY. Full-year revenue guidance raised to at least $180 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.79%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
Rhea-AI Summary
Castle Biosciences to present new data on gene expression profile tests for cutaneous squamous cell carcinoma and melanoma at AHNS conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
52.86%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.47%
Tags
none
-
Rhea-AI Summary
Castle Biosciences grants restricted stock units (RSUs) to 68 employees as an inducement for employment. The RSUs will vest over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
none
Rhea-AI Summary
Castle Biosciences announces new data demonstrating the ability of the DecisionDx-SCC test to identify high-risk tumors in patients with low-risk staging for cutaneous squamous cell carcinoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
-
-
Rhea-AI Summary
Castle Biosciences to present new data on DecisionDx-Melanoma and DecisionDx-UM at ASCO Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
none

FAQ

What is the current stock price of Castle Biosciences (CSTL)?

The current stock price of Castle Biosciences (CSTL) is $29.81 as of November 22, 2024.

What is the market cap of Castle Biosciences (CSTL)?

The market cap of Castle Biosciences (CSTL) is approximately 842.5M.

What does Castle Biosciences specialize in?

Castle Biosciences specializes in diagnostic tests for various cancers, providing genomic information to aid in treatment decisions.

When was Castle Biosciences founded?

Castle Biosciences was founded in 2008.

What types of cancer does Castle Biosciences have tests for?

Castle Biosciences has tests for cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma, and glioma.

What are some of Castle Biosciences' notable products?

Notable products include DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME.

Is Castle Biosciences involved in research for new diagnostic tests?

Yes, they have active research programs in rectal cancer and soft tissue sarcoma, among others.

Where can I find more information about Castle Biosciences and its products?

You can visit their official website at www.castlebiosciences.com for more detailed information.

What is the primary mission of Castle Biosciences?

The primary mission is to provide personalized, clinically actionable genomic information to make more accurate treatment decisions.

Does Castle Biosciences collaborate with other entities?

Yes, they work closely with outstanding members of the oncology community throughout the discovery, development, and utilization of their tests.

What is Castle Biosciences' financial condition?

The company is in a robust financial condition, reflecting successful commercialization efforts and consistent revenue growth.

How does Castle Biosciences contribute to cancer care?

By providing objective and accurate diagnostic tests, Castle Biosciences helps advance cancer care and improve patient outcomes.

Castle Biosciences, Inc.

Nasdaq:CSTL

CSTL Rankings

CSTL Stock Data

842.46M
27.11M
3.25%
95.3%
5.74%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
FRIENDSWOOD